Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.60 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.49 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.42 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.42 |
| ▸ | NMT2 | O60551 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29412683 | 1.00 | FOLH1 (0.60) | FOLH1NOD1GNPATNAALAD2RIMKLA | |
| SCHEMBL29777855 | 1.00 | FOLH1 (0.60) | FOLH1NOD1GNPATNAALAD2RIMKLA | |
| SCHEMBL29451463 | 1.00 | FOLH1 (0.60) | FOLH1NOD1GNPATNAALAD2RIMKLA | |
| SCHEMBL29625397 | 1.00 | FOLH1 (0.60) | FOLH1NOD1GNPATNAALAD2RIMKLA | |
| SCHEMBL30584446 | 1.00 | FOLH1 (0.60) | FOLH1NOD1GNPATNAALAD2RIMKLA | |
| SCHEMBL29774682 | 1.00 | FOLH1 (0.60) | FOLH1NOD1GNPATNAALAD2RIMKLA | |
| SCHEMBL29774675 | 1.00 | FOLH1 (0.60) | FOLH1NOD1GNPATNAALAD2RIMKLA | |
| SCHEMBL30584432 | 1.00 | FOLH1 (0.60) | FOLH1NOD1GNPATNAALAD2RIMKLA | |
| SCHEMBL29777829 | 1.00 | FOLH1 (0.60) | FOLH1NOD1GNPATNAALAD2RIMKLA | |
| SCHEMBL2512125 | 0.95 | FOLH1 (0.53) | FOLH1NOD1GNPATCPB2NMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629446-B2 | Vascular embolic system | 3-D MATRIX, LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| EP-3777875-B1 | SURGICAL METHODS EMPLOYING PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS | 3 D MATRIX LTD (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-20250311587-A1 | VASCULAR EMBOLIC SYSTEM | 3-D MATRIX, LTD. (JP) | 2025-10-02 | — | — | US | disclosed |
| US-12377196-B2 | Preventing biological tissue adhesion | 3-D MATRIX, LTD. (JP) | 2025-08-05 | — | — | US | disclosed |
| US-20250177614-A1 | PREVENTING BIOLOGICAL TISSUE ADHESION | 3-D MATRIX, LTD. (JP) | 2025-06-05 | — | — | US | disclosed |
| EP-3548105-B1 | METHOD FOR PRODUCING A PEPTIDE-BASED NANO FIBER STRUCTURE AND A NANO FIBER STRUCTURE THUS OBTAINED | HUMANA MEDICAL S R L (IT) | 2025-03-05 | — | — | EP | disclosed |
| CN-114341157-B | A series of injectable hydrogels self-assembled from short peptides for various biomedical applications | 新加坡科技研究局 | 2025-02-28 | — | — | CN | disclosed |
| US-12006085-B2 | Fill-finish process for peptide solutions | 3-D MATRIX, LTD. (JP) | 2024-06-11 | — | — | US | disclosed |
| US-11839694-B2 | Compositions and methods for promoting hemostasis and other physiological activities | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230241294-A1 | PREVENTING BIOLOGICAL TISSUE ADHESION | 3-D MATRIX, LTD. (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20220356210-A1 | A SERIES OF INJECTABLE HYDROGELS SELF-ASSEMBLED FROM SHORT PEPTIDES FOR VARIOUS BIOMEDICAL APPLICATIONS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-11-10 | — | — | US | disclosed |
| EP-3429653-B1 | PREVENTING BIOLOGICAL TISSUE ADHESION | 3 D MATRIX LTD (JP) | 2022-11-09 | — | — | EP | disclosed |
| US-20220324601-A1 | FILL-FINISH PROCESS FOR PEPTIDE SOLUTIONS | 3-D MATRIX, LTD. (JP) | 2022-10-13 | — | — | US | disclosed |
| EP-4049671-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | 3D Matrix, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220258900-A9 | FILL-FINISH PROCESS FOR PEPTIDE SOLUTIONS | 3-D MATRIX, LTD. (JP) | 2022-08-18 | — | — | US | disclosed |
| EP-4023240-A1 | PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS AND USES THEREOF | 3D Matrix, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220168462-A1 | VASCULAR EMBOLIC SYSTEM | 3-D MATRIX, LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| EP-4004016-A1 | A SERIES OF INJECTABLE HYDROGELS SELF-ASSEMBLED FROM SHORT PEPTIDES FOR VARIOUS BIOMEDICAL APPLICATIONS | Agency for Science, Technology and Research (SG) | 2022-06-01 | — | — | EP | disclosed |
| US-20220111126-A1 | PREVENTING BIOLOGICAL TISSUE ADHESION | 3-D MATRIX, LTD. (JP) | 2022-04-14 | — | — | US | disclosed |
| CN-114341157-A | A series of injectable hydrogels self-assembled from short peptides for various biomedical applications | 新加坡科技研究局 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629446-B2 | Vascular embolic system | TNNI3, MYLK, ADM2 | FOLH1 1444/4885NOD1 1914/4885GNPAT 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.